Submission to the Canadian Agency for Drugs and Technologies in Health -- Real-world evidence for reporting guidance

Date de parution : 01/06/2023
Personne(s)-ressource(s) : Joan Weir

The insurance industry strongly supports the work of CADTH to develop a standard approach to the reporting of RWE and for highlighting important methodological considerations for those undertaking and submitting RWE studies of healthcare technologies in Canada, including in the area of consent and data sharing. We applaud the direction taken to develop RWE submission principles for Canadian Health Technology Assessment (HTA) agencies, that is, to build upon existing Canadian work in this area and harmonizing current RWE submission principles while maintaining alignment with international standards.